The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization
- PMID: 23264629
- PMCID: PMC3567635
- DOI: 10.1074/jbc.M112.435495
The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization
Abstract
Monoallelic point mutations in cytosolic isocitrate dehydrogenase 1 (IDH1) and its mitochondrial homolog IDH2 can lead to elevated levels of 2-hydroxyglutarate (2HG) in multiple cancers. Here we report that cellular 2HG production from cytosolic IDH1 mutation is dependent on the activity of a retained wild-type IDH1 allele. In contrast, expression of mitochondrial IDH2 mutations led to robust 2HG production in a manner independent of wild-type mitochondrial IDH function. Among the recurrent IDH2 mutations at Arg-172 and Arg-140, IDH2 Arg-172 mutations consistently led to greater 2HG accumulation than IDH2 Arg-140 mutations, and the degree of 2HG accumulation correlated with the ability of these mutations to block cellular differentiation. Cytosolic IDH1 Arg-132 mutations, although structurally analogous to mutations at mitochondrial IDH2 Arg-172, were only able to elevate intracellular 2HG to comparable levels when an equivalent level of wild-type IDH1 was co-expressed. Consistent with 2HG production from cytosolic IDH1 being limited by substrate production from wild-type IDH1, we observed 2HG levels to increase in cancer cells harboring an endogenous monoallelic IDH1 mutation when mitochondrial IDH flux was diverted to the cytosol. Finally, expression of an IDH1 construct engineered to localize to the mitochondria rather than the cytosol resulted in greater 2HG accumulation. These data demonstrate that allelic and subcellular compartment differences can regulate the potential for IDH mutations to produce 2HG in cells. The consequences of 2HG elevation are dose-dependent, and the non-equivalent 2HG accumulation resulting from IDH1 and IDH2 mutations may underlie their differential prognosis and prevalence in various cancers.
Figures
Similar articles
-
Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.Oncogene. 2012 May 10;31(19):2491-8. doi: 10.1038/onc.2011.416. Epub 2011 Sep 26. Oncogene. 2012. PMID: 21996744 Free PMC article.
-
Reductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells.Int J Biochem Cell Biol. 2015 Aug;65:125-33. doi: 10.1016/j.biocel.2015.05.012. Epub 2015 May 22. Int J Biochem Cell Biol. 2015. PMID: 26007236
-
2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.PLoS One. 2011 Feb 4;6(2):e16812. doi: 10.1371/journal.pone.0016812. PLoS One. 2011. PMID: 21326614 Free PMC article.
-
Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability.Cold Spring Harb Perspect Med. 2024 May 2;14(5):a041537. doi: 10.1101/cshperspect.a041537. Cold Spring Harb Perspect Med. 2024. PMID: 38191174 Review.
-
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.Genes Dev. 2013 Apr 15;27(8):836-52. doi: 10.1101/gad.217406.113. Genes Dev. 2013. PMID: 23630074 Free PMC article. Review.
Cited by
-
IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas.Neuro Oncol. 2018 Apr 9;20(5):716-718. doi: 10.1093/neuonc/noy014. Neuro Oncol. 2018. PMID: 29522183 Free PMC article. No abstract available.
-
Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.Elife. 2016 Feb 26;5:e12626. doi: 10.7554/eLife.12626. Elife. 2016. PMID: 26943899 Free PMC article.
-
IDH inhibition in gliomas: from preclinical models to clinical trials.Nat Rev Neurol. 2024 Jul;20(7):395-407. doi: 10.1038/s41582-024-00967-7. Epub 2024 May 17. Nat Rev Neurol. 2024. PMID: 38760442 Review.
-
Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia.Leukemia. 2024 May;38(5):927-935. doi: 10.1038/s41375-024-02246-2. Epub 2024 Apr 10. Leukemia. 2024. PMID: 38600315 Free PMC article. Review.
-
Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm.Blood Cancer J. 2021 Jun 3;11(6):107. doi: 10.1038/s41408-021-00497-1. Blood Cancer J. 2021. PMID: 34083508 Free PMC article. Review.
References
-
- Mardis E. R., Ding L., Dooling D. J., Larson D. E., McLellan M. D., Chen K., Koboldt D. C., Fulton R. S., Delehaunty K. D., McGrath S. D., Fulton L. A., Locke D. P., Magrini V. J., Abbott R. M., Vickery T. L., Reed J. S., Robinson J. S., Wylie T., Smith S. M., Carmichael L., Eldred J. M., Harris C. C., Walker J., Peck J. B., Du F., Dukes A. F., Sanderson G. E., Brummett A. M., Clark E., McMichael J. F., Meyer R. J., Schindler J. K., Pohl C. S., Wallis J. W., Shi X., Lin L., Schmidt H., Tang Y., Haipek C., Wiechert M. E., Ivy J. V., Kalicki J., Elliott G., Ries R. E., Payton J. E., Westervelt P., Tomasson M. H., Watson M. A., Baty J., Heath S., Shannon W. D., Nagarajan R., Link D. C., Walter M. J., Graubert T. A., DiPersio J. F., Wilson R. K., Ley T. J. (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058–1066 - PMC - PubMed
-
- Parsons D. W., Jones S., Zhang X., Lin J. C., Leary R. J., Angenendt P., Mankoo P., Carter H., Siu I. M., Gallia G. L., Olivi A., McLendon R., Rasheed B. A., Keir S., Nikolskaya T., Nikolsky Y., Busam D. A., Tekleab H., Diaz L. A., Jr., Hartigan J., Smith D. R., Strausberg R. L., Marie S. K., Shinjo S. M., Yan H., Riggins G. J., Bigner D. D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V. E., Kinzler K. W. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807–1812 - PMC - PubMed
-
- Yan H., Parsons D. W., Jin G., McLendon R., Rasheed B. A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G. J., Friedman H., Friedman A., Reardon D., Herndon J., Kinzler K. W., Velculescu V. E., Vogelstein B., Bigner D. D. (2009) IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773 - PMC - PubMed
-
- Dang L., White D. W., Gross S., Bennett B. D., Bittinger M. A., Driggers E. M., Fantin V. R., Jang H. G., Jin S., Keenan M. C., Marks K. M., Prins R. M., Ward P. S., Yen K. E., Liau L. M., Rabinowitz J. D., Cantley L. C., Thompson C. B., Vander Heiden M. G., Su S. M. (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739–744 - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
